{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:18:42Z","timestamp":1789953522830,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd006687.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T00:00:00Z","timestamp":1341964800000}}],"reference-count":118,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006687.pub3","type":"journal-article","created":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T19:31:28Z","timestamp":1341603088000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Oral vasodilators for primary Raynaud's phenomenon"],"prefix":"10.1002","author":[{"given":"Marlene","family":"Stewart","sequence":"first","affiliation":[{"name":"University of Edinburgh; Centre for Population Health Sciences; Teviot Place Edinburgh UK EH8 9AG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne R","family":"Morling","sequence":"additional","affiliation":[{"name":"University of Edinburgh; Centre for Population Health Sciences; Teviot Place Edinburgh UK EH8 9AG"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,11]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD006687.pub3-BIB0001|cit1","first-page":"739P","article-title":"Clinical and physiological assessment of angiotensin-converting enzyme inhibition in primary Raynaud's phenomenon","volume":"28","author":"Challenor","year":"1989","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.1991.tb05565.x","article-title":"Subjective and objective assessment of enalapril in primary Raynaud's phenomenon","volume":"31","author":"Challenor","year":"1991","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0002-9343(84)90101-3","article-title":"Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon","volume":"77","author":"Ettinger","year":"1984","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9343(85)90402-4","article-title":"Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation","volume":"78","author":"Malamet","year":"1984","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0005|cit5","first-page":"751","article-title":"Reproducibility of cold provocation in patients with Raynaud's Phenomenon","volume":"14","author":"Wigley","year":"1987","journal-title":"Journal of Rheumatology"},{"issue":"11-12","key":"10.1002\/14651858.CD006687.pub3-BIB0006|cit6","first-page":"343","article-title":"Thymoxamine for Raynaud's disease and chilblains","volume":"34","author":"Jaffe","year":"1980","journal-title":"British Journal of Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/000331979104200405","article-title":"Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up","volume":"42","author":"Quentrec","year":"1991","journal-title":"Angiology"},{"issue":"36","key":"10.1002\/14651858.CD006687.pub3-BIB0008|cit8","first-page":"2695","article-title":"[Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study","volume":"146","author":"Madsen","year":"1984","journal-title":"Ugeskrift for Laeger"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.1987.tb07356.x","article-title":"The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon","volume":"117","author":"Rustin","year":"1987","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub3-BIB0010|cit10","first-page":"657","article-title":"Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial","volume":"2","author":"Wal","year":"1985","journal-title":"Microcirculation, Endothelium and Lymphatics"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0011|cit11","first-page":"313","article-title":"The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study","volume":"6","author":"Wal","year":"1987","journal-title":"International Angiology"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub3-BIB0012|cit12","first-page":"1917","article-title":"Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes","volume":"23","author":"Vayssairat","year":"1996","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0013|cit13","first-page":"19","article-title":"Effect of long-term ketanserin treatment on 5-HT levels, platelet-aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study","volume":"7","author":"Arneklo-Nobin","year":"1988","journal-title":"International Angiology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/000331977802900107","article-title":"Pathophysiology of capillary circulation: Raynaud's disease","volume":"29","author":"Arnot","year":"1978","journal-title":"Angiology"},{"issue":"7","key":"10.1002\/14651858.CD006687.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/000331978904000705","article-title":"Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon","volume":"40","author":"Arosio","year":"1989","journal-title":"Angiology"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/000331979104200509","article-title":"Efficacy of ketanserin in the therapy of Raynaud's phenomenon: thermometric data","volume":"42","author":"Arosio","year":"1991","journal-title":"Angiology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0017|cit17","first-page":"13","article-title":"Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study","volume":"20","author":"Bali","year":"2011","journal-title":"Acta Dermatovenerologica Alpina, Panonica et Adriatica"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"113S","DOI":"10.1111\/j.1365-2125.1983.tb02119.x","article-title":"Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial","volume":"15","author":"Belch","year":"1983","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0019|cit19","unstructured":"Belch JJF Cormie J Pinkerton L Lowe GDO Capell H Forbes CD Evaluation of UK-37248: A thromboxane synthatase inhibitor, in the treatment of Raynaud's syndrome Haemostasis 1982 179-Abstract No 330"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.54.3.197","article-title":"Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study","volume":"54","author":"Belch","year":"1995","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0021|cit21","first-page":"39","article-title":"Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl","volume":"5","author":"Bounameaux","year":"1986","journal-title":"International Angiology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FJC.0b013e31823c0bed","article-title":"No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary raynaud phenomenon: a randomized controlled trial","volume":"59","author":"Bredie","year":"2012","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/1523-1747.ep12465175","article-title":"Digital cutaneous vascular responses to histamine and neuropeptides in Raynaud's phenomenon","volume":"96","author":"Bunker","year":"1991","journal-title":"The Journal of Investigative Dermatology"},{"issue":"8863","key":"10.1002\/14651858.CD006687.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0140-6736(93)91286-U","article-title":"Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon","volume":"342","author":"Bunker","year":"1993","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0248-8663(85)80042-4","article-title":"Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2). [French] Trial treatment of severe Raynaud's phenomenon with prostacyclin (PG12)","volume":"6","author":"Cabane","year":"1985","journal-title":"Revue de Medecine Interne"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archinte.166.2.231","article-title":"Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease","volume":"166","author":"Caglayan","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0027|cit27","first-page":"655","article-title":"Vardenafil in patients with raynaud's syndrome","volume":"32","author":"Caglayan","year":"2011","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10067-008-1084-9","article-title":"To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud's phenomenon in South Korea; Korean Raynaud study (KOARA study)","volume":"28","author":"Choi","year":"2009","journal-title":"Clinical Rheumatology"},{"issue":"Suppl.2","key":"10.1002\/14651858.CD006687.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1097\/00005344-198600082-00018","article-title":"Effect of indoramin on finger circulation in patients with Raynaud disease","volume":"8","author":"Clement","year":"1986","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/000331978403501105","article-title":"Therapeutic efficacy of alpha-adrenoceptor blockade in primary and secondary Raynaud's syndrome","volume":"35","author":"Cleophas","year":"1984","journal-title":"Angiology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/000331978403500104","article-title":"Treatment of Raynaud's syndrome with adrenergic alpha-blockade with or without beta-blockade","volume":"35","author":"Cleophas","year":"1984","journal-title":"Angiology"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/000331978904000206","article-title":"Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon","volume":"40","author":"Codella","year":"1989","journal-title":"Angiology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0002-9343(89)80148-2","article-title":"International study of ketanserin in Raynaud's phenomenon","volume":"87","author":"Coffman","year":"1989","journal-title":"The American Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD006687.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/000331978103201002","article-title":"Double-blind capillaroscopic study of the activity of buflomedil in Raynaud's syndrome: a report on 80 cases","volume":"32","author":"Courbier","year":"1981","journal-title":"Angiology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mvr.2011.04.004","article-title":"The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome","volume":"82","author":"Csiki","year":"2011","journal-title":"Microvascular Research"},{"issue":"36","key":"10.1002\/14651858.CD006687.pub3-BIB0037|cit37","first-page":"1322","article-title":"Double-blind clinical evaluation of naftidrofuryl in Raynaud's phenomenon","volume":"69","author":"Davinroy","year":"1993","journal-title":"Semaine des Hopitaux"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0038|cit38","first-page":"34","article-title":"Assessment of pinacidil in patients with primary Raynaud's phenomenon","volume":"34","author":"Dompeling","year":"1992","journal-title":"Vasa - Supplementum"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0950-821X(88)80014-8","article-title":"The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon","volume":"2","author":"Dormandy","year":"1988","journal-title":"European Journal of Vascular Surgery"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/09537109009009192","article-title":"Platelet aggregation in primary Raynaud's phenomenon and the effect of enalapril administration","volume":"1","author":"Dowie","year":"1990","journal-title":"Platelets"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0262-1746(85)90143-X","article-title":"The effect of a prostacyclin analogue (Iloprost) on skin temperature","volume":"19","author":"Drury","year":"1985","journal-title":"Prostaglandins Leukotrienes and Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0042|cit42","first-page":"168","article-title":"Trial of a new drug in Raynaud's disease. Clinical and thermographic control","volume":"18","author":"Dumoulin","year":"1981","journal-title":"Electrodiagnostic Therapie"},{"issue":"12","key":"10.1002\/14651858.CD006687.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/sj.clpt.6100103","article-title":"The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon","volume":"81","author":"Friedman","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"19","key":"10.1002\/14651858.CD006687.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy [see comment]","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"issue":"2-3","key":"10.1002\/14651858.CD006687.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0049-3848(92)90196-H","article-title":"Thromboxane does not play a significant role in acute, cold-induced vasoconstriction in Raynaud's phenomenon. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism","volume":"66","author":"Gresele","year":"1992","journal-title":"Thrombosis Research"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0950-821X(89)80066-0","article-title":"The efficacy of thymoxamine in primary Raynaud's phenomenon","volume":"3","author":"Grigg","year":"1989","journal-title":"European Journal of Vascular Surgery"},{"issue":"38","key":"10.1002\/14651858.CD006687.pub3-BIB0048|cit48","first-page":"1090","article-title":"Treatment of peripheral arterial insufficiency with inositol nicotinate (Hexanit)","volume":"76","author":"Hentzer","year":"1966","journal-title":"Nordisk Medicin"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2177\/jsci.19.193","article-title":"The effect of beraprost sodium on the Raynaud's phenomenon","volume":"19","author":"Hiida","year":"1996","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/030006057900700601","article-title":"An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon","volume":"7","author":"Holti","year":"1979","journal-title":"Journal of International Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.1988.tb00171.x","article-title":"Enalapril in Raynaud's phenomenon","volume":"13","author":"Janini","year":"1988","journal-title":"Journal of Clincal Pharmacy and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0262-1746(83)90068-9","article-title":"A thromboxane synthetase inhibitor in Raynaud's phenomenon","volume":"12","author":"Jones","year":"1983","journal-title":"Prostaglandins Leukotrienes and Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006687.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/oxfordjournals.eurheartj.a061923","article-title":"Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon","volume":"6","author":"Kahan","year":"1985","journal-title":"European Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub3-BIB0054|cit54","first-page":"1403","article-title":"Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon","volume":"19","author":"Kyle","year":"1992","journal-title":"Journal of Rheumatology"},{"issue":"Suppl.7","key":"10.1002\/14651858.CD006687.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1097\/00005344-198500077-00028","article-title":"Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon","volume":"7","author":"Longstaff","year":"1985","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/clpt.1984.147","article-title":"Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon","volume":"36","author":"Luderer","year":"1984","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0057|cit57","first-page":"Article ID 5807","article-title":"Results of a pilot randomized placebo-controlled trial in primary and secondary Raynaud's Phenomenon with St. John's Wort: Detecting changes in angiogenic cytokines when RP improves","author":"Malenfant","year":"2011","journal-title":"ISRN Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00561375","article-title":"Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon","volume":"35","author":"Marasini","year":"1988","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/03009740310004711","article-title":"Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon","volume":"33","author":"Marasini","year":"2004","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0060|cit60","first-page":"127","article-title":"Action of Buflomedil on the cutaneous microcirculation studied by a Cold provocation test. Multicentre double-blind placebo controlled trial","volume":"20","author":"Maurel","year":"1995","journal-title":"Journal des Maladies Vasculaires"},{"issue":"7","key":"10.1002\/14651858.CD006687.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/000331978703800706","article-title":"Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon","volume":"38","author":"Meloni","year":"1987","journal-title":"Angiology"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.44.11.754","article-title":"A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome","volume":"44","author":"Mohrland","year":"1985","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub3-BIB0063|cit63","first-page":"521","article-title":"The effect of inositol nicotinate (Hexopal) in patients with Raynaud's phenomenon. A placebo-controlled study","volume":"22","author":"Murphy","year":"1985","journal-title":"Clinical Trials Journal"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0064|cit64","unstructured":"NCT00048763 Safety and efficacy of pletal (cilostazol) for the treatment of juvenile primary and secondary Raynaud's phenomenon http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00048763?term=nct00048763&rank=1"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0065|cit65","unstructured":"NCT00048776 Safety and efficacy of pletal (cilostazol) for the treatment of juvenile primary and secondary Raynaud's phenomenon http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00048776?term=nct00048776&rank=1"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0066|cit66","unstructured":"NCT01233999 Botulinum toxin in the treatment of Raynaud's http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01233999?term=nct01233999&rank=1"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00610065","article-title":"Prazosin treatment of primary Raynaud's phenomenon","volume":"24","author":"Nielsen","year":"1983","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6155","key":"10.1002\/14651858.CD006687.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.1.6155.20-a","article-title":"Effects of naftidrofuryl on microcirculatory cold sensitivity in Raynaud's phenomenon","volume":"1","author":"Nilsen","year":"1979","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1997.00219.x","article-title":"The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon","volume":"242","author":"Pancera","year":"1997","journal-title":"Journal of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0070|cit70","first-page":"215","article-title":"Raynaud's phenomenon: effects of terazosin","volume":"45","author":"Paterna","year":"1997","journal-title":"Minerva Cardioangiologica"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/000331979304400206","article-title":"New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin","volume":"44","author":"Pola","year":"1993","journal-title":"Angiology"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","article-title":"Effects of cilostazol in patients with Raynaud's syndrome","volume":"92","author":"Rajagopalan","year":"2003","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0073|cit73","first-page":"94","article-title":"Prazosin treatment of Raynaud's phenomenon: A double blind single crossover study","volume":"12","author":"Russell","year":"1985","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0074|cit74","first-page":"61","article-title":"A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome","volume":"27","author":"Rustin","year":"1984","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/03009738409179501","article-title":"Blood viscosity, finger systolic pressure and effect of dazoxiben treatment in primary vasospastic disease","volume":"89","author":"Sandhagen","year":"1984","journal-title":"Upsala Journal of Medical Sciences"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/art.1780270204","article-title":"Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor","volume":"27","author":"Seibold","year":"1984","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0077|cit77","first-page":"337","article-title":"Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon","volume":"13","author":"Seibold","year":"1986","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2125.1991.tb03883.x","article-title":"Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin","volume":"32","author":"Shawket","year":"1991","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0079|cit79","first-page":"14","article-title":"Captopril therapy of Raynaud's syndrome","volume":"Issue 1","author":"Shcherbakov","year":"1992","journal-title":"Revmatologiia"},{"issue":"12","key":"10.1002\/14651858.CD006687.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02284056","article-title":"A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease","volume":"7","author":"Sunderland","year":"1988","journal-title":"Clinical Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2362.1985.tb00138.x","article-title":"Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon","volume":"15","author":"Tindall","year":"1985","journal-title":"European Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0083|cit83","first-page":"249","article-title":"Ketanserin and capillary flow in Raynaud's phenomenon","volume":"9","author":"Tooke","year":"1990","journal-title":"International Journal of Microcirculation-Clinical and Experimental"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Tooke JE Williams SA Rawlinson DW Black C The effects of ketanserin on capillary flow in Raynaud's phenomenon Clinical Science 1987 74P","DOI":"10.1042\/cs072074Pb"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0085|cit85","first-page":"157","article-title":"A double blind randomised comparison of two doses of iloprost in the treatment of Raynauds phenomenon","volume":"35","author":"Torley","year":"1990","journal-title":"Scottish Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0086|cit86","first-page":"37","article-title":"Treatment of Raynaud's phenomenon with captopril","volume":"13","author":"Tosi","year":"1987","journal-title":"Drugs Under Experimental and Clinical Research"},{"issue":"9191","key":"10.1002\/14651858.CD006687.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(99)04095-7","article-title":"Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial","volume":"354","author":"Tucker","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0088|cit88","first-page":"306","article-title":"A comparative study of trifluoperazine a calmodulin inhibitor, nifedipine, dipyridamole and intraarterial reserpine in the treatment of raynaud's phenomenon: a double blind randomised controlled trial","volume":"35","author":"Wasir","year":"1983","journal-title":"Indian Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00615400","article-title":"Sublingual and oral isoxsuprine in patients with Raynaud's phenomenon","volume":"20","author":"Wesseling","year":"1981","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0090|cit90","first-page":"80","article-title":"Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon","volume":"21","author":"Wise","year":"1994","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/clpt.1986.166","article-title":"Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon","volume":"40","author":"Wollersheim","year":"1986","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD006687.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/j.1552-4604.1988.tb05720.x","article-title":"Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side-effects","volume":"28","author":"Wollersheim","year":"1988","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0093|cit93","unstructured":"NCT01090492 PF-00489791 for the treatment of Raynaud's http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01090492?term=raynaud&rank=1"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0094|cit94","unstructured":"ATC 2007 Anatomical Therapeutical Chemical Classification, WHO http:\/\/www.whocc.no\/atcddd"},{"issue":"9273","key":"10.1002\/14651858.CD006687.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","article-title":"Raynaud's phenomenon","volume":"357","author":"Block","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0096|cit96","unstructured":"British National Formulary BNF53 http:\/\/www.bnf.org\/bnf\/"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0097|cit97","volume-title":"Medical statistics: A commonsense approach","author":"Campbell","year":"1999"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00393-006-0068-x","article-title":"[Evidence-based therapy of Raynaud's syndrome","volume":"65","author":"Distler","year":"2006","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","article-title":"Defining the clinically important difference in pain outcome measures","volume":"88","author":"Farrar","year":"2000","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub3-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002069.pub3","article-title":"Calcium channel blockers for primary Raynaud's Phenomenon (Protocol)","author":"Herrick","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0103|cit103","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (Updated September 2006) www.cochrane.org\/resources\/handbook\/hbook.htm"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/art.21912","article-title":"Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance","volume":"54","author":"Hirschl","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/03009749850154311","article-title":"Raynaud's phenomenon: State of the Art 1998","volume":"27","author":"Ho","year":"1998","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"7400","key":"10.1002\/14651858.CD006687.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0108|cit108","unstructured":"Medicines.org.uk electronic Medicines Compendium (eMC) www.medicines.org.uk"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"15","key":"10.1002\/14651858.CD006687.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA-Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0111|cit111","unstructured":"Pope J Raynaud's Phenomenon (primary) http:\/\/www.clinicalevidence.com\/ceweb\/conditions\/cvd\/1119\/1119.jsp"},{"key":"10.1002\/14651858.CD006687.pub3-BIB0112|cit112","unstructured":"Prodigy Guidance Raynaud's phenomenon http:\/\/www.cks.library.nhs.uk\/raynauds_phenomenon"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"6752","key":"10.1002\/14651858.CD006687.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/bmj.301.6752.590","article-title":"Prevalence of symptoms of Raynaud's phenomenon in general practice","volume":"301","author":"Silman","year":"1990","journal-title":"British Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archinte.158.6.595","article-title":"Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases","volume":"158","author":"Spencer-Green","year":"1998","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology"},{"issue":"13","key":"10.1002\/14651858.CD006687.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Clinical practice. Raynaud's phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub3-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006687.pub2","article-title":"Oral vasodilators for primary Raynaud's phenomenon","author":"Vinjar","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006687.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006687.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:02:44Z","timestamp":1628546564000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006687.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,7,11]]},"references-count":118,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006687.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006687.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,11]]}}}